Domain-Independent Inhibition of CBP/p300 Attenuates α-Synuclein Aggregation

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Neurodegenerative diseases involve protein misfolding and aggregation, notably alpha-synuclein in Parkinson's disease.
• CBP and p300 are key proteins involved in protein modification and recognition, making them potential therapeutic targets.

Purpose of the Study:

• To investigate the role of CBP and p300 in alpha-synuclein aggregation.
• To evaluate selective CBP/p300 inhibitors as a therapeutic strategy for Parkinson's disease.

Main Methods:

• Utilized high-affinity inhibitors (A-485, GNE-049, SGC-CBP30) targeting CBP and p300.
• Assessed the impact of these inhibitors on alpha-synuclein aggregation in primary mouse embryonic dopaminergic neurons.

Main Results:

• Selective CBP/p300 inhibitors demonstrated an ability to alter pathological alpha-synuclein accumulation.
• Drug-like CBP/p300 inhibitors effectively reduced alpha-synuclein aggregation.

Conclusions:

• CBP and p300 are viable targets for attenuating alpha-synuclein aggregation.
• Systemic administration of CBP/p300 inhibitors represents a promising therapeutic approach for Parkinson's disease and related disorders.